BrainCool

BrainCool AB reports that the American Medical Association (AMA) have announced the approval of a new Current Procedural Terminology (CPT®) code for reduction of complications associated with oral mucositis in patients undergoing chemotherapy, thereby creating a clear path for reimbursement of the Cooral® System.
 
The new CPT code, an action resulted from the AMA CPT Editorial Panel’s September 21st - 23rd 2023 meeting, will become effective for use in 2024, and establishing a pathway for widespread adoption and reimbursement. Worth highlighting is that the code application was included by the CPT Committee as a ‘consent’ application. Meaning the application was approved without further discussions and a vote.
 
CEO Martin Waleij comments
-” This is a major milestone for Cooral® System, and most of all for patients suffering from oral mucositis as a result from cancer treatment. It further recognizes BrainCool’s innovative technology of Cooral® System, with the creation of a new unique procedure category”.